Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
View Patent ↗A crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug and methods of preparing a crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug, and methods of using a crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug are provided.
1. The compound crystalline calcium (3S)-{[(1R)-isobutanoyloxyethoxy]carbonylaminomethy}-5-methyl-hexanoate hydrate, which exhibits characteristic scattering angles (2α) at least at 5.1°±0.2°, 7.3°±0.2°, 8.0°±0.2°, 11.6°±0.2° and 16.3°±0.2° in an X-ray powder diffractogram measured using Cu—Kα radiation.
2. The compound of claim 1 , comprising from 1 mole water per mole of the compound to 3 moles water per mole of the compound.
3. The compound of claim 1 , comprising from 2 wt % water to 5 wt % water.
4. The compound of claim 1 , which exhibits a melting point range from 107° C. to 111° C.
5. The compound of claim 1 , wherein the compound is crystalline calcium 3-({[(1R)-1-(2-methylpropanoyloxy)ethoxy]-carbonylamino}methyl)(3S)-5-methylhexanoic acid monohydrate.
6. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable vehicle.
7. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition is a sustained release oral dosage formulation.
8. The pharmaceutical composition of claim 6 , comprising an agent chosen from an opioid agonist, a selective serotonin re-uptake inhibitor, and a selective noradrenaline re-uptake inhibitor.
9. The pharmaceutical composition of claim 6 , comprising an opioid agonist.
10. The pharmaceutical composition of claim 9 , wherein the opioid agonist is chosen from tramadol, tapentadol, and oxycodone.
11. The pharmaceutical composition of claim 9 , wherein the ratio of the amount of compound of claim 1 to the amount of opioid agonist in the pharmaceutical composition is from 1:4 to 4:1.
12. The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition is a sustained release oral dosage formulation.
13. The pharmaceutical composition of claim 12 , wherein the sustained release oral dosage formulation comprises:
50 mg to 1200 mg of the compound of claims 1 ; and
10 mg to 400 mg of the opioid agonist.
14. A method of preparing the compound crystalline calcium (3S)-{[(1R)-isobutanoyloxyethoxy]carbonylaminomethyl}-5-methyl-hexanoate hydrate, which exhibits characteristic scattering angles (2α) at least at 5.1°±0.2°, 7.3°±0.2°, 8.0°±0.2°, 11.6°±0.2° and 16.3°±0.2° in an X-ray powder diffractogram measured using Cu—Kα radiation by steps comprising:
providing a solution comprising calcium (3S)-{[(1R)-isobutanoyloxyethoxy]carbonylaminomethyl}-5-methyl-hexanoate, water, and a water-miscible solvent; and
adjusting the temperature of the solution to provide crystalline calcium (3S)-{[(1R)-isobutanoyloxyethoxy]carbonylaminomethy}-5-methyl-hexanoate hydrate.
15. The method of claim 14 , wherein the water-miscible solvent is chosen from ethanol and isopropanol.
16. The method of claim 14 , wherein the solution comprises water in an amount ranging from about 40 v/v % to about 75 v/v %.
17. The method of claim 14 , wherein the compound is prepared by steps comprising:
providing a first solution comprising calcium (3S)-{[(1R)-isobutanoyloxyethoxy]carbonylaminomethyl}-5-methyl-hexanoate and an alcoholic solvent;
adding de-ionized water to the first solution to provide a mixture;
adjusting the temperature of the mixture to provide a second solution; and
adjusting the temperature of the second solution to provide crystalline calcium (3S)-{[(1R)-isobutanoyloxyethoxy]carbonylaminomethyl}-5-methyl-hexanoate hydrate.
18. The method of claim 17 , wherein the alcoholic solvent is chosen from ethanol and isopropanol.
19. A method of managing chronic pain in a patient comprising administering to a patient in need of such treatment a pharmaceutical composition comprising:
the compound crystalline calcium (3S)-{[(1R)-isobutanoyloxyethoxy]carbonylaminomethyl}-5-methyl-hexanoate, which exhibits characteristic scattering angles (2α) at least at 5.1°±0.2°, 7.3°±0.2°, 8.0°±0.2°, 11.6°±0.2° and 16.3°±0.2° in an X-ray powder diffractogram measured using Cu—Kα;
an agent chosen from an opioid agonist, a selective serotonin re-uptake inhibitor, and a selective noradrenaline re-uptake inhibitor; and
a pharmaceutically acceptable vehicle.
20. The method of claim 19 , wherein the agent is an opioid agonist.
21. The method of claim 19 , wherein the opioid agonist is chosen from tramadol, tapentadol, and oxycodone.